Skip to main content
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease logoLink to Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
. 2026 Sep 9;15(19):e047678. doi: 10.1161/JAHA.125.047678

Role of Thrombectomy Technique in Alteplase Bridging Intravenous Thrombolysis for Basilar Artery Occlusion

Muhammad Jaffar 1,#, Kazi Ahmed 1,#, Samir Abu‐Rumeileh 2, Markus Otto 2, Lorenzo Barba 2, Thanh N Nguyen 3, Mohamad Abdalkader 3, Piers Klein 3, Kyriakos Lobotesis 4, Mariarosaria Valente 5, Gian Luigi Gigli 5, Soumik Talukder 1, Gabriele Prandin 6, Liqun Zhang 7, Matteo Foschi 8,9, Giovanni Merlino 5,10, Robert Simister 11, Soma Banerjee 1,12, Lucio D'Anna 1,12,✉
PMCID: PMC13745129  PMID: 42757922

Abstract

Background

Endovascular treatment (EVT) is the standard of care for acute basilar artery occlusion (BAO) although the role of bridging intravenous thrombolysis (IVT) with alteplase prior to EVT remains debated. Whether the effect of bridging IVT differs across EVT techniques has not been systematically assessed.

Methods

We conducted a retrospective multicenter analysis including consecutive patients with BAO treated with EVT at 7 comprehensive stroke centers between 2019 and 2023. Patients were stratified according to first‐line thrombectomy technique: direct thromboaspiration (BAOTA), stent retriever (BAOST), or combined approach (BAOCO). Outcomes were analyzed using inverse probability weighting to adjust for baseline imbalances. The primary end point was 90‐day favorable functional outcome (modified Rankin Scale 0–3) and ordinal 90‐day modified Rankin Scale shift. Secondary end points included 90‐day functional independence (modified Rankin Scale 0–2), successful reperfusion, 90‐day mortality, hemorrhagic transformation, and symptomatic intracerebral hemorrhage. Sensitivity analyses with trimmed weights and subgroup analyses were prespecified.

Results

A total of 517 patients were included: 200 BAOTA, 260 BAOST, and 57 BAOCO. In patients with BAOTA, bridging IVT was associated with higher rates of 90‐day favorable outcome (risk ratio [RR] 1.47, 95% CI 1.00–2.16) and improved 90‐day modified Rankin Scale shift. In patients with BAOST bridging IVT significantly reduced symptomatic intracerebral hemorrhage risk (RR 0.27, 95% CI 0.09–0.77) while in patients with BAOCO functional independence was numerically more frequent among patients treated with bridging IVT (RR 1.91, 95% CI 1.08–3.37).

Conclusions

Bridging IVT was associated with differences in clinical and safety outcomes across EVT strategies. However, no statistically significant interaction was observed between treatment allocation and EVT technique. Therefore, these findings should be interpreted as descriptive and hypothesis‐generating rather than evidence of true differences in treatment effect.

Keywords: aspiration, basilar artery occlusion, combined approach, stent retriever

Subject Categories: Ischemic Stroke


Nonstandard Abbreviations and Acronyms

BAO

basilar artery occlusion

BAOCO

basilar artery occlusion treated with combined thrombectomy technique

BAOST

basilar artery occlusion treated with stent retriever thrombectomy

BAOTA

basilar artery occlusion treated with direct thromboaspiration

EVT

endovascular therapy

IPW

inverse probability weighting

IVT

intravenous thrombolysis

mRS

modified Rankin Scale

NIHSS

National Institutes of Health Stroke Scale

RD

risk difference

sICH

symptomatic intracranial hemorrhage

SMD

standardized mean difference

TICI

thrombolysis in cerebral infarction

Clinical Perspective.

What Is New?

  • In this multicenter observational study, bridging intravenous thrombolysis was associated with distinct patterns of clinical and safety outcomes across different endovascular therapy strategies in patients with basilar artery occlusion.

  • While no statistically significant interaction was observed, these findings highlight potential differences that warrant further investigation.

What Are the Clinical Implications?

  • These results provide additional insight into the relationship between bridging intravenous thrombolysis and outcomes across different thrombectomy approaches; the observed patterns should be interpreted with caution and may inform future studies aimed at better understanding potential differences across procedural strategies.

Recent randomized trials have demonstrated benefit for the use of endovascular treatment (EVT) in selected patients with basilar artery occlusion (BAO). 1 , 2 However, the role of bridging intravenous thrombolysis (IVT) in patients with BAO – the so‐called bridging approach‐ remains a matter of debate. 3 Indeed, emerging evidence suggest a potential benefit of bridging IVT in promoting earlier recanalization and better functional recovery, without a clear increase in hemorrhagic complications. 4 , 5 Nonetheless, these findings largely rely on heterogeneous, non‐randomized cohorts, and robust, confirmatory evidence is still lacking. Importantly, the choice of EVT technique may also influence the clinical efficacy of bridging IVT in patients with acute stroke due to BAO. EVT can be performed using different approaches, including direct thromboaspiration, stent retriever, or a combined strategy that integrates both modalities. These techniques are characterized by distinct procedural success rates, reperfusion dynamics, and safety profiles, which could potentially modify the effect of IVT on clinical outcomes. 6 , 7 , 8 , 9 Recent data from a post hoc analysis of the Solitaire™ With the Intention For Thrombectomy Plus Intravenous t‐PA Versus DIRECT Solitaire™ Stent‐retriever Thrombectomy in Acute Anterior Circulation Stroke (SWIFT‐DIRECT) trial suggest that the effect of bridging IVT may vary according to stent retriever–based thrombectomy techniques in anterior circulation large vessel occlusion. 10 Yet, this potential interaction has not been systematically investigated in patients with BAO undergoing EVT.

In this multicenter study, we investigated whether the effect of bridging IVT varies according to the first‐line endovascular technique employed—direct thromboaspiration, stent retriever thrombectomy, or a combined approach. Focusing exclusively on BAO cases treated with EVT, we assessed clinical outcomes, safety profiles, and procedural performance across all 3 approaches.

METHODS

This study has obtained approval from the UK Health Regulator Authority (HRA Reference No.: 275260). The study has also received confirmation of capacity and capability from the Imperial College Healthcare NHS Trust. Informed consent was not a legal requirement as the research was performed using data collected as part of routine care and any researchers outside the direct care team only had access to anonymized data. Data available upon reasonable request.

Database and Population

This is an observational retrospective multicenter real‐world study of prospectively collected data. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. 11 We enrolled consecutive patients with acute ischemic stroke attributable to isolated BAO undergoing EVT from 7 comprehensive stroke centers (Charing Cross Hospital, Imperial College Healthcare NHS Trust, London (UK); St George's University of London, London (UK); University College London Hospitals, London, (UK); Martin‐Luther‐University Halle‐Wittenberg, Halle (Saale), (Germany); Udine University Hospital, Udine, (Italy); Boston Medical Center, Boston, Massachusetts, (USA); AUSL Romagna, (Italy)) between January 2019 and December 2023. BAO was confirmed by baseline computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography. Patients with concurrent occlusions involving the vertebral arteries, posterior cerebral arteries, or anterior circulation were excluded. Additionally, cases with incomplete data on the thrombectomy approach were excluded from the analysis. BAO was initially identified on CTA or MRA at presentation and subsequently confirmed by digital subtraction angiography at the time of the endovascular procedure. In cases of discordance between non‐invasive imaging and angiography, final inclusion was based on angiographic findings, and only patients with occlusion confined to the basilar artery were retained for analysis. The choice of EVT technique was left to the discretion of the treating neuro‐interventionalist. Peri‐procedural intra‐arterial medications included the administration of alteplase and nimodipine as indicated. Clinical decisions regarding treatment with EVT and IVT were made in accordance with current national and international guidelines. IVT was given within 4.5 hours from symptom onset or, when applicable, from the last time seen well. Patients with clearly unknown onset who did not meet guideline‐based eligibility criteria were not treated with intravenous thrombolysis. Alteplase was used as the thrombolytic agent; tenecteplase was not administered at any participating center. Clinical and radiological assessments were performed by local neurologists and neuro‐interventionalists at each site. The modified Rankin Scale (mRS) score at 90 days was determined either through an in‐person follow‐up visit or via structured telephone interview. All data were reviewed for plausibility, integrity, and completeness using a standardized protocol. In cases of data inconsistency, queries were issued to the respective centers for clarification.

Study Outcomes

The 2 primary effectiveness outcomes were 90‐day favorable mRS (0–3) and the mRS shift after 90 days, assessed through ordinal regression analysis indicating the shift towards higher mRS scores (worse functional outcome). Functional outcome evaluated by local stroke neurologists. Secondary effectiveness outcome parameters included successful recanalization (defined as a modified thrombolysis in cerebral infarction (TICI) score of 2b to 3), 90‐day functional independence mRS score (0–2). Safety outcomes comprised 90‐day mortality, symptomatic intracerebral hemorrhage (sICH) and any hemorrhagic transformation assessed by intracranial imaging at 24 hours. Hemorrhagic transformation was evaluated in accordance with the Heidelberg classification, which includes all hemorrhagic subtypes. 12 sICH was defined as any ICH associated with neurological worsening of ≥4 points on the National Institutes of Health Stroke Scale (NIHSS) score, not attributable to other causes. 13

Statistical Analysis

Inverse probability weighting (IPW) analyses were performed to evaluate the effect of bridging IVT on clinical, safety, and procedural outcomes in patients with basilar artery occlusion treated with EVT. The first analysis compared outcomes between patients treated with EVT plus IVT and those treated with EVT alone in the overall study cohort. Then, we compared clinical, safety, and procedural outcomes according to the first‐line EVT technique, including direct thromboaspiration, stent retriever thrombectomy, and the combined approach. Propensity scores were estimated using a logistic regression model including prespecified demographic, clinical, and procedural covariates in the overall BAO cohort. Stabilized inverse probability weights were derived and applied to create a weighted pseudo‐population in which treatment allocation was independent of measured confounders. These weights were used for the primary overall analysis as well as for subsequent stratified analyses by first‐line EVT technique. Covariate balance before and after weighting was assessed using standardized mean differences (SMD), with absolute values <0.10 considered indicative of adequate balance. For each EVT‐technique subgroup (BAOTA, BAOST, and BAOCO), propensity scores and inverse probability weights were estimated separately. Categorical variables are reported as counts and percentages, and continuous variables as means with SDs or medians with interquartile ranges, as appropriate. Baseline balance was assessed using standardized mean differences (SMD), with absolute values below 0.1 considered indicative of adequate covariate balance. For binary outcomes, including favorable functional outcome at 90 days (mRS 0–3), functional independence (mRS 0–2), successful reperfusion (TICI 2b–3), mortality at 90 days, hemorrhagic transformation, and symptomatic intracranial hemorrhage (sICH), risk ratios (RRs) were estimated using survey‐weighted generalized linear models with a log link. Absolute treatment effects were quantified as marginal risk differences (RDs) estimated using G‐computation based on survey‐weighted logistic regression models. Predicted outcome probabilities were calculated under both treatment strategies (EVT alone and EVT plus IVT), and the average difference between these counterfactual risks was used to derive the RD. CIs for RDs were obtained using non‐parametric bootstrap resampling. The ordinal distribution of mRS scores at 90 days was analyzed using a generalized linear model with cumulative logit link. Results were expressed as a common odds ratio (OR) with 95% CIs, representing the overall shift across the ordered mRS categories under the proportional odds assumption. All outcome analyses were conducted in the IPW‐weighted cohorts. To formally assess whether the effect of bridging intravenous thrombolysis differed according to first‐line EVT technique, interaction terms between treatment allocation (EVT+IVT versus EVT alone) and EVT technique were tested within the inverse probability–weighted models for the primary outcome (90‐day mRS score 0–3). As a sensitivity analysis, we repeated all outcome comparisons within each EVT technique after applying trimming of inverse probability weights to reduce the influence of extreme values. For each group (aspiration, stent retriever, and combined approach), stabilized weights were truncated at the 1st and 99th percentiles, and a survey‐weighted design was constructed using the trimmed weights. Generalized linear models were then fitted to estimate risk ratios with a log link and risk differences with an identity link for binary outcomes, and proportional odds logistic regression was used for ordinal outcomes. The identity link was used to directly estimate risk differences, and model predictions were checked to ensure that estimated probabilities remained within valid bounds. This trimming‐based approach allowed us to verify the robustness of the main findings across all 3 thrombectomy techniques by minimizing the potential bias introduced by extreme weights. As a sensitivity analysis, the primary outcome analysis was repeated after excluding patients treated beyond 6 hours from symptom onset while retaining patients with unknown onset time. In this restricted cohort, inverse probability–weighted models were refitted to estimate risk ratios and marginal risk differences for the study outcomes, to assess the robustness of the main findings to treatment timing. Prespecified subgroup analyses for the primary outcome were performed according to age (<80 versus ≥80 years), sex, baseline NIHSS (<10 versus ≥10), Posterior Circulation Alberta Stroke Program Early CT Score (≥7 versus <7), and pre‐hospital model of care (mothership versus drip‐and‐ship). These analyses were considered exploratory. In prespecified subgroup analyses, interaction terms between bridging intravenous thrombolysis and key baseline variables (age, sex, baseline NIHSS, pre‐hospital model of care, and baseline ASPECTS) were tested for the primary functional outcome. All statistical analyses were conducted using R software (version 4.2), and a 2‐sided P value <0.05 was considered statistically significant.

RESULTS

A total of 517 patients with acute BAO were included in the study, of whom 266 (51.4%) EVT alone and 251 (48.6%) received bridging IVT followed by EVT (Figure S1 and Table S1). Among these, 200 patients (38.7%) were treated as first line with direct thromboaspiration (BAOTA), 260 (50.3%) with stent retriever thrombectomy (BAOST), and 57 (11.0%) with a combined approach (BAOCO) (Figure S1). Baseline characteristics of the overall BAO cohort according to treatment allocation are reported in Table S1. Patients treated with EVT alone and EVT plus IVT were broadly comparable in terms of age, sex, vascular risk factors, and stroke severity at admission. Stroke etiology according to Trial of Org 10 172 in Acute Stroke Treatment classification differed significantly between groups (P=0.004), with a higher proportion of cardioembolic strokes in the EVT‐only group and a higher proportion of undetermined etiology among patients with EVT plus IVT. To account for baseline and workflow‐related differences, inverse probability of treatment weighting was applied. As shown in Table S2, covariate balance improved after weighting, with standardized mean differences below 0.1 for most covariates. However, onset‐to‐groin time remained above the predefined threshold (SMD >0.1), indicating residual imbalance for this variable. Pre‐weighting imbalances in onset‐to‐groin time (SMD 0.51), pre‐stroke mRS (SMD 0.26), ASPECTS (SMD 0.19), and known atrial fibrillation (SMD 0.13) were reduced after weighting. EVT‐only patients were less often treated within 3 to 6 hours from onset compared with patients with EVT plus IVT (42.1% versus 58.6%) (Table S3). After weighting, differences across onset‐to‐groin categories were attenuated and no longer statistically significant (Rao–Scott adjusted P=0.089). Study outcomes for the overall cohort are summarized in Table S4.

In IPW‐adjusted analyses, bridging IVT was associated with a higher likelihood of favorable functional outcome at 90 days (RR 1.32, 95% CI 1.08–1.61; RD +13.5%, 95% CI 3.8–22.9) and a favorable shift in the overall mRS distribution (OR 0.59, 95% CI 0.41–0.84; P=0.004). A similar association was observed for functional independence (RR 1.31, 95% CI 1.03–1.66). Bridging IVT was also associated with a significantly lower risk of sICH (RR 0.45, 95% CI 0.24–0.84), without evidence of increased risk of hemorrhagic transformation or 90‐day mortality. Rates of successful reperfusion did not differ significantly between groups. Finally, a sensitivity analysis excluding patients treated beyond 6 hours from onset while retaining those with unknown onset is presented in Table S5. In this restricted cohort, the association between bridging IVT and favorable functional outcome persisted (RR 1.27, 95% CI 1.02–1.59; RD +10.9%, 95% CI 0.8–21.3). No statistically significant interaction was observed between treatment allocation (EVT+IVT versus EVT alone) and first‐line EVT technique for the primary outcome of 90‐day mRS 0–3 (P for interaction=0.350), indicating no evidence of treatment effect heterogeneity across EVT techniques.

Bridging Intravenous Thrombolysis in Patients With BAO Treated With Thromboaspiration Technique

Among patients with BAOTA, 97 underwent EVT alone and 103 received bridging intravenous thrombolysis (EVT+IVT) (Table 1). After IPW, baseline demographic and clinical characteristics were well balanced between the 2 groups, with standardized mean differences below 0.1 for all major covariates (Figure S2). Before weighting, patients in the EVT+IVT group had a lower prevalence of known atrial fibrillation (P=0.001) and the use of oral anticoagulation on admission was more frequent among EVT‐only patients (P=0.001). The median onset‐to‐groin time was significantly shorter in the EVT+IVT group (P=0.027).

Table 1.

Baseline Characteristics of the Patients With BAO Treated With Thromboaspiration Technique

BAOTA P value SMD unweighted SMD weighted
EVT (N=97) EVT+IVT (N=103)
Demographics
Age, median (IQR), y 72 (60–79) 68 (56–80) 0.553 0.079 0.060
Sex, male, n (%) 54 (56) 54 (52) 0.672 0.032 0.004
Risk factors
Hypertension, n (%) 58 (60) 48 (47) 0.067 0.132 0.042
Diabetes, n (%) 13 (13) 14 (14) 1.000 0.002 0.006
Dyslipidemia, n (%) 20 (21) 18 (18) 0.593 0.031 0.007
Coronary artery disease, n (%) 4 (4) 12 (12) 0.067 0.075 0.001
Stroke or TIA history, n (%) 13 (13) 14 (14) 1.000 0.007 0.015
ICH history, n (%) 0 (0) 0 (0) NA
Frequent alcohol use, n (%) 3 (3) 3 (3) 1.000 0.002 0.001
Current/Former smoker, n (%) 12 (12) 17 (17) 0.429 0.041 0.002
Known atrial fibrillation, n (%) 29 (30) 11 (11) 0.001 0.192 0.037
AFDAS, n (%) 14 (14) 20 (19) 0.452 0.049 0.026
Heart failure, n (%) 24 (25) 25 (24) 1.000 0.005 0.016
Pre stroke mRS n (%) 0.274 0.145 0.010
0 45 (46) 50 (49)
1 48 (50) 53 (52)
2 2 (2) 0 (0)
3 2 (2) 0 (0)
Therapy on admission
Antiplatelet treatment, n (%) 12 (12) 14 (14) 0.836 0.012 0.008
Oral anticoagulation, n (%) 9 (9) 0 (0) 0.001 0.092 0.045
Acute ischemic stroke characteristics
NIHSS on admission, median (IQR) 16 (10–23) 17 (10–20) 0.412 0.145 0.026
PC‐ASPECTS, median (IQR) 9 (9–10) 10 (9–10) 0.350 0.132 0.021
Known onset n (%) 44 (45) 55 (53) 0.262 0.080 0.031
Procedural features
Pre‐hospital model of care, n (%) 1.000 0.009 0.026
Mothership 31 (32) 32 (31)
Drip‐and‐ship 66 (68) 71 (69)
Onset to groin time (min), median (IQR) 280 (210–359) 235 (189–318) 0.027 0.479 0.031
No. of passes, median (IQR) 2 (1–2) 2 (1–3) 0.682 0.102 0.005
First pass successful, n (%) 38 (39) 45 (44) 0.567 0.045 0.013

AFDAS indicates atrial fibrillation detected after stroke; BAO, basilar artery occlusion; EVT, endovascular therapy; ICH, intracerebral hemorrhage; IQR, interquartile range; IVT, intravenous thrombolysis; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PC‐ASPECTS, Posterior Circulation Alberta Stroke Program Early CT Score; SMD, standardized mean difference; and TIA, transient ischemic attack.

Regarding the study outcomes (Table 2), after IPW, patients with BAOTA treated with EVT+IVT showed a significant higher rate of 90‐day favorable mRS (0–3) compared to patients treated with EVT alone (RR 1.47 [95% CI 1.00–2.16]; P=0.049) (RD 17.2 [95% CI 1.7–33]; P=0.040) (Table 2). The 90‐day mRS shift analysis documented with lower mRS in patients with BAOTA treated with EVT+IVT compared with patients treated with EVT only for BAO (OR 0.57, 95% CI 0.32–0.98; P=0.044) (Figure 1 and Table 2) indicating a favorable shift across the entire mRS distribution. There were no significant differences in the rate of 90‐day functional independence mRS score (0–2) and rates of successful reperfusion (TICI 2b–3) between the 2 groups. Similarly, rate of mortality at 90 days, occurrence of hemorrhagic transformation or sICH were comparable between groups. Details of sensitivity analysis are reported in Data S1 and Table S6.

Table 2.

Study Outcomes in Patients With BAO Treated With Thromboaspiration Technique

BAOTA Statistical metric Treatment difference [95% CI] P value
EVT (N=97) EVT+IVT (N=103)
Primary outcomes
90‐d mRS score 0–3, n (%) 34 (35) 57 (55) Risk ratio

1.47

[1.00–2.16]

0.049
Risk difference (%) 17.2 [1.7 to 33.0] 0.040
90‐d mRS score distribution Odds ratio 0.57 [0.32–0.98] 0.044
No symptoms (score of 0), n (%) 8 (8) 18 (17)
Symptoms without any disability (score of 1), n (%) 12 (12) 17 (17)
Symptoms with mild disability (score of 2), n (%) 8 (8) 13 (13)
Symptoms with mild‐to‐moderate disability (score of 3), n (%) 6 (6) 9 (8)
Symptoms with moderate‐to‐severe disability (score of 4), n (%) 17 (18) 11 (11)
Symptoms with severe disability (score of 5), n (%) 12 (13) 10 (10)
Death (score of 6), n (%) 34 (35) 25 (24)
Secondary outcomes
90‐d mRS score 0–2, n (%) 28 (29) 48 (47) Risk ratio 1.37 [0.88–2.15] 0.165
Risk difference (%) 12.0 [−4.5 to 27.5] 0.150
Post‐procedural favorable TICI score, n (%) 36 (37) 39 (38) Risk ratio 1.11 [0.74–1.67] 0.613
Risk difference (%) 4.2 [−12.2 to 19.9] 0.610
Safety outcomes
90‐d death, n (%) 34 (35) 25 (24) Risk ratio 0.71 [0.43–1.15] 0.164
Risk difference (%) −10.2 [−24.1 to 4.2] 0.170
Post‐procedural HT, n (%) 25 (26) 29 (28) Risk ratio 1.37 [0.81–2.32] 0.241
Risk difference (%) 8.0 [−5.2 to 20.5] 0.230
Symptomatic ICH, n (%) 7 (7) 9 (9) Risk ratio 1.17 [0.41–3.35] 0.766
Risk difference (%) 1.3 [−6.6 to 9.3] 0.750

BAO indicates basilar artery occlusion; HT, hemorrhagic transformation; EVT, endovascular therapy; ICH, intracerebral hemorrhage; IVT, intravenous thrombolysis; mRS, modified Rankin Scale; and TICI, thrombolysis in cerebral infarction.

Figure 1. Ninety‐day mRS score distribution in patients with BAO treated with thromboaspiration, comparing EVT alone versus EVT+IVT.

Figure 1

The OR with 95% CI represents the common OR derived from a cumulative logit (ordinal logistic) model, reflecting the overall shift across the ordered mRS categories. BAO, basilar artery occlusion; EVT, endovascular therapy; IVT, intravenous thrombolysis; mRS, modified Rankin Scale; and OR, odds ratio.

Subgroup analyses in patients with BAOTA for favorable functional outcome (mRS 0–3 at 90 days) are shown in Table S7 and Figure S5. Treatment with EVT+IVT was associated with the incremental probability of 90‐day favorable outcome (mRS 0–3) in patients aged ≥80 years (RD 25.0 [95% CI 8.3–43.8]; P=0.007), among female patients (RD 22.4 [95% CI 0.6–42.1]; P=0.037), those with baseline NIHSS ≥10 (RD 18.7 [95% CI 0.4–36.3]; P=0.038). Moreover, we observed that also in patients with BAOTA managed via the drip‐and‐ship model (RD 25.9 [95% CI 8.8–41.8]; P=0.003) and baseline ASPECTS ≥7 (RD 19.7 [95% CI 3.6–35.4]; P=0.019) showed a greater magnitude of association favoring treatment with EVT+IVT; however, formal tests for interaction were not statistically significant, and these findings should be interpreted as exploratory.

Bridging Intravenous Thrombolysis in Patients With BAO Treated With Stent Retriever Technique

Baseline characteristics of patients with BAOST are presented in Table 3. Overall, the 2 treatment groups, EVT alone (n=134) and EVT combined with IVT (n=126), showed broadly comparable demographic and clinical features. After IPW, baseline demographic and clinical characteristics were well balanced between the 2 groups, with standardized mean differences below 0.1 for all major covariates (Figure S3). Before weighting, patients in the EVT+IVT group had a lower prevalence of smoking (P=0.016). Known symptom onset was more frequent in EVT plus IVT patients (83% versus 66%, P=0.002). First‐pass success was achieved more often in the EVT group (63% versus 47%, P=0.013), whereas other procedural features did not differ substantially.

Table 3.

Baseline Characteristics of the Patients With BAO Treated With Stent Technique

BAOST P value SMD unweighted SMD weighted
EVT (N=134) EVT+IVT (N=126)
Demographics
Age, median (IQR), y 69 (57–79) 65 (54–85) 0.148 0.155 0.127
Sex, male, n (%) 71 (53) 60 (48) 0.457 0.053 0.005
Risk factors
Hypertension, n (%) 74 (55) 73 (58) 0.708 0.027 0.010
Diabetes, n (%) 29 (22) 18 (14) 0.147 0.002 0.006
Dyslipidemia, n (%) 41 (31) 31 (25) 0.332 0.059 0.007
Coronary artery disease, n (%) 21 (16) 18 (14) 0.862 0.014 0.007
Stroke or TIA history, n (%) 18 (13) 8 (6) 0.065 0.071 0.018
ICH history, n (%) 0 (0) 0 (0) NA
Frequent alcohol use, n (%) 10 (8) 4 (3) 0.171 0.042 0.021
Current/Former smoker, n (%) 44 (33) 24 (19) 0.016 0.137 0.035
Known atrial fibrillation, n (%) 33 (25) 23 (18) 0.230 0.064 0.036
AFDAS, n (%) 21 (16) 15 (12) 0.473 0.038 0.001
Heart failure, n (%) 11 (8) 11 (9) 1.000 0.005 0.005
Pre stroke mRS, n (%) 0.156 0.294 0.004
0 80 (60) 85 (68)
1 37 (28) 35 (28)
2 11 (8) 6 (5)
3 2 (2) 0 (0)
4 1 (1) 0 (0)
5 1 (1) 0 (0)
Therapy on admission
Antiplatelet treatment, n (%) 13 (10) 17 (14) 0.438 0.037 0.015
Oral anticoagulation, n (%) 19 (14) 11 (9) 0.180 0.054 0.025
Acute ischemic stroke characteristics
NIHSS on admission, median (IQR) 17 (8–23) 17 (9–24) 0.361 0.129 0.059
PC‐ASPECTS, median (IQR) 9 (8–10) 9 (9–10) 0.057 0.247 0.068
Known onset, n (%) 88 (66) 105 (83) 0.002 0.176 0.050
Procedural features
Pre‐hospital model of care, n (%) 0.385 0.060 0.021
Mothership 74 (55) 62 (49)
Drip‐and‐ship 60 (45) 64 (51)
Onset to groin time (min), median (IQR) 300 (300–300) 300 (300–300) 0.070 0.459 0.199
No. of passes, median (IQR) 1 (1–2) 1 (1–2) 0.541 0.113 0.012
First pass successful, n (%) 84 (63) 59 (47) 0.013 0.159 0.016

AFDAS indicates atrial fibrillation detected after stroke; BAO, basilar artery occlusion; EVT, endovascular therapy; ICH, intracerebral hemorrhage; IQR, interquartile range; IVT, intravenous thrombolysis; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PC‐ASPECTS, Posterior Circulation Alberta Stroke Program Early CT Score; SMD, standardized mean difference; and TIA, transient ischemic attack.

Study outcomes are summarized in Table 4. After IPW, in patients with BAOST there were no significant differences in the rate of 90‐day favorable mRS score (0–3). Similarly, no significant difference was observed in the ordinal mRS shift analysis, indicating no overall shift across the mRS distribution between EVT+IVT and EVT alone groups (Figure 2). Similarly, there were no significant differences in the rate of 90‐day functional independence (mRS 0–2) and favorable reperfusion (TICI 2b–3) between the 2 groups. In terms of safety outcomes, mortality at 90 days and rate of hemorrhagic transformation were similar between the 2 groups. However, we documented a significant lower rate of sICH in patients with BAOST treated with EVT+IVT compared with EVT alone (RR 0.27, 95% CI 0.09–0.77, P=0.014; RD −11.2%, 95% CI −19.4 to −3.8; P=0.010). Details of sensitivity analysis are reported in Data S1 and Table S8.

Table 4.

Study Outcomes in Patients With BAO Treated With Stent Technique

BAOST Statistical metric Treatment difference [95% CI] P value
EVT (N=134) EVT+IVT (N=126)
Primary outcomes
90‐d mRS score 3–5, n (%) 58 (43) 69 (55) Risk ratio 1.05 [0.78 to 1.41] 0.761
Risk difference (%) 2.3 [−12.0 to 18.7] 0.760
90‐d mRS score distribution Odds ratio 0.90 [0.52 to 1.56] 0.714
No symptoms (score of 0), n (%) 12 (9) 19 (15)
Symptoms without any disability (score of 1), n (%) 18 (13) 23 (18)
Symptoms with mild disability (score of 2), n (%) 18 (13) 14 (11)
Symptoms with mild‐to‐moderate disability (score of 3), n (%) 10 (8) 13 (10)
Symptoms with moderate‐to‐severe disability (score of 4), n (%) 13 (10) 17 (14)
Symptoms with severe disability (score of 5), n (%) 14 (10) 4 (3)
Death (score of 6), n (%) 49 (37) 36 (29)
Secondary outcomes
90‐d mRS score 0–2, n (%) 48 (36) 56 (44) Risk ratio 0.98 [0.69 to 1.38] 0.889
Risk difference (%) −1.1 [−14.8 to 14.5] 0.890
Post‐procedural favorable TICI score, n (%) 87 (65) 94 (75) Risk ratio 1.04 [0.88 to 1.24] 0.622
Risk difference (%) 3.1 [−8.9 to 16.5] 0.630
Safety outcomes
90‐d death, n (%) 49 (37) 36 (29) Risk ratio 1.01 [0.64 to 1.58] 0.963
Risk difference (%) 0.3 [−15.1 to 13.9] 0.960
Post‐procedural HT, n (%) 37 (28) 27 (21) Risk ratio 0.68 [0.41 to 1.14] 0.145
Risk difference (%) −8.9 [−21.3 to 3.1] 0.150
Symptomatic ICH, n (%) 25 (19) 5 (4) Risk ratio 0.27 [0.09 to 0.77] 0.014
Risk difference (%) −11.2 [−19.4 to −3.8] 0.010

BAO indicates basilar artery occlusion; BAOST, basilar artery occlusion treated with stent retriever thrombectomy, HT, hemorrhagic transformation; ICH, intracerebral hemorrhage; mRS, modified Rankin Scale; and TICI, thrombolysis in cerebral infarction.

Figure 2. Ninety ‐day mRS score distribution in patients with BAO treated with stent retriever thrombectomy, comparing EVT alone versus EVT+IVT.

Figure 2

The OR with 95% CI represents the common OR derived from a cumulative logit (ordinal logistic) model, reflecting the overall shift across the ordered mRS categories. BAO, basilar artery occlusion; EVT, endovascular therapy; IVT, intravenous thrombolysis'; mRS, modified Rankin Scale; and OR, odds ratio.

Subgroup analyses in patients with BAOST for favorable functional outcome (mRS 0–3 at 90 days) are shown in Table S9 and Figure S6. Across the variables of interest, no significant treatment interactions were identified, with similar outcomes regardless of the age, sex, NIHSS at baseline, pre‐hospital model of care and baselines ASPECTS score. However, formal tests for interaction between treatment allocation and subgroup variables did not reach statistical significance for age, sex, baseline NIHSS, pre‐hospital model of care, or ASPECTS.

Bridging Intravenous Thrombolysis in Patients With BAO Treated With Combined Technique

Baseline characteristics of patients with BAOCO are reported in Table 5. A total of 35 patients underwent EVT alone and 22 received EVT combined with IVT. After IPW, baseline demographic and clinical characteristics were well balanced between the 2 groups, with standardized mean differences below 0.1 for all major covariates (Figure S4). Before weighting, known onset was significantly more frequent in the EVT plus IVT group (P<0.001). Median onset‐to‐groin time was longer in the EVT group (P<0.001). The number of passes was higher in EVT (P=0.002), whereas first‐pass success was achieved at similar rates (P=0.335).

Table 5.

Baseline Characteristics of the Patients With BAO Treated With Combined Technique

BAOCO P value SMD unweighted SMD weighted
EVT (N=35) EVT+IVT (N=22)
Demographics
Age, median (IQR), y 66 (57–80) 68 (61–75) 0.896 0.058 0.180
Sex, male, n (%) 18 (51) 10 (46) 1.000 0.059 0.011
Risk factors
Hypertension, n (%) 19 (54) 12 (55) 1.000 0.002 0.005
Diabetes, n (%) 11 (31) 5 (23) 0.555 0.087 0.031
Dyslipidemia, n (%) 10 (29) 6 (27) 1.000 0.013 0.008
Coronary artery disease, n (%) 7 (20) 5 (23) 1.000 0.027 0.001
Stroke or TIA history, n (%) 6 (17) 3 (14) 1.000 0.035 0.017
ICH history, n (%) 0 (0) 0 (0) NA
Frequent alcohol use, n (%) 7 (20) 2 (10) 0.458 0.109 0.200
Current/Former smoker, n (%) 10 (29) 2 (10) 0.103 0.195 0.009
Known atrial fibrillation, n (%) 15 (43) 7 (32) 0.577 0.110 0.017
AFDAS, n (%) 14 (40) 4 (18) 0.142 0.218 0.001
Heart failure, n (%) 2 (6) 3 (14) 0.364 0.079 0.057
Pre stroke mRS, n (%) 0.786 0.471 0.061
0 20 (57) 16 (73)
1 9 (26) 5 (23)
2 3 (9) 1 (5)
3 2 (6) 0 (0)
4 1 (3) 0 (0)
Therapy on admission
Antiplatelet treatment, n (%) 2 (6) 7 (32) 0.020 0.026 0.005
Oral anticoagulation, n (%) 2 (6) 3 (14) 0.364 0.079 0.148
Acute ischemic stroke characteristics
NIHSS on admission, median (IQR) 16 (9–24) 16 (6–25) 0.980 0.026 0.333
PC‐ASPECTS, median (IQR) 9 (9–10) 9 (8–10) 0.554 0.276 0.197
Known onset, n (%) 15 (43) 22 (100) <0.001 0.571 0.571
Procedural features
Pre‐hospital model of care, n (%) 0.788 0.048 0.143
Mothership 19 (54) 13 (59)
Drip‐and‐ship 16 (46) 9 (41)
Onset to groin time (min), median (IQR) 300 (300–635) 300 (283–300) <0.001 0.799 0.719
No. of passes, median (IQR) 2 (1–2) 1 (1–1) 0.002 0.811 0.314
First pass successful, n (%) 26 (74) 19 (86) 0.335 0.120 0.143

AFDAS indicates atrial fibrillation detected after stroke; BAO, basilar artery occlusion; EVT, endovascular therapy; ICH, intracerebral hemorrhage; IQR, interquartile range; IVT, intravenous thrombolysis; mRS, modified ranking scale; NIHSS, National Institutes of Health Stroke Scale; PC‐ASPECTS, Posterior Circulation Alberta Stroke Program Early CT Score; SMD, standardized mean difference; and TIA, transient ischemic attack.

Study outcomes are summarized in Table S10. After IPW, there were no significant differences in the rate of 90‐day favorable mRS score (0–3) in patients with BAOCO. Similarly, no significant difference was observed in the ordinal mRS shift analysis, indicating no overall shift across the mRS distribution between EVT+IVT and EVT alone groups (Figure 3). Similarly, there were no significant differences in the rate favorable reperfusion (TICI 2b–3) between the 2 groups. Functional independence (mRS 0–2) was numerically more frequent among patients treated with EVT+IVT than among those treated with EVT alone, with a significant relative association but wide uncertainty around the marginal absolute effect estimate (RR 1.91, 95% CI 1.08–3.37, P=0.026; RD 29%, 95% CI −26 to 75; P=0.260). In terms of safety outcomes, mortality at 90 days, rate of hemorrhagic transformation and sICH were similar between the 2 groups. Details of sensitivity analysis are reported in Data S1 and Table S11. In Table S12 and Figure S7, the subgroup analysis of in patients with BAOCO showed no statistically significant heterogeneity across clinical and procedural strata.

Figure 3. Ninety‐day modified mRS score distribution (grouped) in patients with BAO treated with a combined technique, comparing EVT alone versus EVT+.

Figure 3

Outcomes are categorized as independence (mRS 0–2), dependence (mRS 3–5), and death (mRS 6). The OR with 95% CI represents the common OR derived from a cumulative logit (ordinal logistic) model, reflecting the overall shift across the ordered mRS categories. BAO, basilar artery occlusion; EVT, endovascular therapy; IVT, intravenous thrombolysis; mRS, modified Rankin Scale; and OR, odds ratio.

DISCUSSION

In this multicenter observational study of patients with BAO treated with EVT, we investigated whether the association between bridging intravenous thrombolysis and clinical outcomes differed according to the first‐line thrombectomy technique. We observed that, across EVT strategies, bridging IVT was associated with distinct patterns of outcomes, including higher rates of favorable 90‐day outcome and improved disability shift in patients treated with thromboaspiration, a lower risk of sICH in those undergoing stent retriever thrombectomy. Importantly, the formal test for interaction did not demonstrate statistically significant heterogeneity across EVT techniques. Therefore, the observed differences in subgroup‐specific estimates should be interpreted as descriptive and hypothesis‐generating rather than evidence of true effect modification. Overall, these findings suggest that, while the association between bridging IVT and outcomes may present differently across procedural contexts, such observations require confirmation in future studies specifically designed to assess treatment effect heterogeneity.

The role of IVT prior to EVT in BAO has been a subject of considerable debate. 3 Some studies have suggested a potential for earlier recanalization and better functional outcomes, 14 , 15 , 16 , 17 whereas others have failed to demonstrate a clear advantage, 1 , 18 , 19 , 20 , 21 , 22 , 23 raising questions about the added value of bridging therapy. Importantly, previous studies have largely treated EVT as a single entity, without accounting for the diversity of thrombectomy techniques. In this context, our findings suggest that the association between bridging IVT and clinical outcomes may differ in its observed patterns across procedural strategies. In patients treated with thromboaspiration, bridging IVT was associated with higher rates of favorable 90‐day outcomes and improved disability shift. These observations are mechanistically plausible, as IVT may soften the thrombus and facilitate aspiration, potentially reducing the need for multiple passes and improving the efficiency of recanalization. 24 , 25 Additionally, IVT may contribute to distal emboli dissolution and microvascular reperfusion, thereby supporting neurological recovery. 26 By contrast, in patients treated with stent retriever thrombectomy, bridging IVT was not associated with improved functional outcomes but was associated with a lower rate of sICH compared with EVT alone. This finding is noteworthy, as bridging therapy has traditionally raised concerns regarding increased hemorrhagic risk when combined with mechanical thrombectomy. Several procedural and pathophysiological mechanisms may potentially explain this observation. IVT may promote partial thrombus softening and improve clot integration within the stent retriever, possibly reducing the need for repeated or forceful device deployment and retrieval. This may, in turn, limit endothelial disruption and perforator injury, which are recognized contributors to procedure‐related hemorrhage in posterior circulation stroke. In addition, IVT may reduce distal embolization and no‐reflow phenomena, thereby attenuating reperfusion‐related parenchymal injury. 27 Taken together, these findings suggest that, within the context of stent retriever thrombectomy, bridging IVT may be associated with a favorable safety profile. However, these observations did not translate into measurable functional benefit and should be interpreted cautiously given the observational design of the study. Importantly, no statistically significant interaction was observed across EVT techniques, and therefore these differences should be considered descriptive and hypothesis‐generating rather than evidence of true effect modification.

In patients with BAOCO, bridging IVT was associated with a numerically higher rate of functional independence at 90 days. These patients often present with more resistant or complex occlusions, and IVT may contribute to partial thrombus lysis that complements both aspiration and stent retrieval. 28 , 29 Although statistical significance was not reached for all end points, these observations should be interpreted with caution given the limited sample size and the exploratory nature of this subgroup. When considered across the 3 thrombectomy techniques, these findings highlight differences in the observed associations between bridging IVT and specific clinical and safety outcomes. However, in the absence of statistically significant interaction, these variations should be regarded as descriptive and hypothesis‐generating rather than evidence of true differences in treatment effect. These results contribute to the ongoing discussion on the role of bridging therapy in BAO and provide a framework for future studies specifically designed to evaluate potential treatment effect heterogeneity across procedural strategies.

Subgroup analyses also provide important insights. In patients with BAOTA, IVT was particularly beneficial in elderly individuals, women, and those with severe strokes, suggesting that the additive effect of IVT may be greatest in clinically high‐risk subgroups. Patients treated in a drip‐and‐ship model also appeared to benefit more, likely because IVT provides earlier reperfusion during inter‐hospital transfer delays. 30 , 31 By contrast, no clear treatment interactions were detected in patients with BAOST, supporting the notion that EVT alone is effective in this context, while bridging IVT contributes mainly to safety rather than efficacy. These nuanced results highlight the importance of patient selection and procedural tailoring when considering bridging therapy in clinical practice.

An additional point to consider is that all patients in the present study received alteplase as the bridging thrombolytic agent. However, recent evidence and evolving clinical practice have increasingly supported the use of tenecteplase in acute ischemic stroke, including in the setting of large vessel occlusion. 32 Emerging data suggest potential differences in pharmacodynamic properties and reperfusion profiles between alteplase and tenecteplase, which may influence treatment effects when combined with endovascular therapy. 33 In this context, the findings of the present study should be interpreted within the framework of alteplase‐based bridging therapy. Whether similar patterns of association would be observed with tenecteplase remains uncertain and warrants further investigation. Future studies specifically designed to compare thrombolytic agents in conjunction with different thrombectomy strategies will be essential to better define optimal treatment paradigms in basilar artery occlusion.

There are limitations to acknowledge. The retrospective, observational design means residual confounding cannot be excluded, despite the use of inverse probability weighting. The choice of EVT technique and IVT administration was not randomized and may have been influenced by local practice or operator preference. The sample size for the combined technique subgroup was modest, which reduces the precision of effect estimates, limiting statistical power and increasing the risk of chance findings. Accordingly, results from this subgroup should be considered exploratory and hypothesis‐generating rather than definitive evidence of treatment effect modification. Residual confounding related to workflow and treatment timing cannot be entirely excluded despite inverse probability weighting, particularly in smaller technique‐specific subgroups such as patients treated with a combined thrombectomy approach. Standardized assessment of clot burden and posterior circulation collateral status was not available across participating centers and therefore could not be included in the analyses. Nevertheless, the multicenter design, inclusion of a large real‐world BAO cohort, and consistency of findings across techniques enhance the robustness of our conclusions.

In conclusion, this multicenter analysis shows that bridging IVT was associated with differences in clinical and safety outcomes in patients with BAO treated with EVT. Across thrombectomy strategies, distinct patterns of association were observed, including improved functional outcomes in aspiration‐treated patients, reduced symptomatic hemorrhage in stent retriever–treated patients, and higher rates of functional independence in those undergoing combined approaches. However, no statistically significant interaction was observed between treatment allocation and EVT technique, and therefore these findings should be interpreted as descriptive and hypothesis‐generating rather than evidence of true differences in treatment effect. These results contribute to the ongoing discussion regarding the role of bridging therapy in BAO. Future randomized studies, ideally stratified by endovascular approach, are warranted to further investigate potential treatment effect heterogeneity in this high‐risk population.

Sources of Funding

None.

Disclosures

SB is a key opinion leader for RAPIDAI. TNN is Associate Editor of Stroke; advisory board for Brainomix, Aruna Bio; speaker for Genentech, Kaneka. RS is partially funded by the UCLH Biomedical Research Centre. The remaining authors have no disclosures to report.

Supporting information

STROBE checklist

Tables S1‐S12

Figures S1‐S7

This manuscript was sent to Adriana B. Conforto, MD, PhD, Guest Editor, for review by expert referees, editorial decision, and final disposition.

For Sources of Funding and Disclosures, see page 13.

References

  • 1. Jovin TG, Li C, Wu L, Wu C, Chen J, Jiang C, Shi Z, Gao Z, Song C, Chen W, et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar‐artery occlusion. N Engl J Med. 2022;387:1373–1384. doi: 10.1056/NEJMoa2207576. [DOI] [PubMed] [Google Scholar]
  • 2. Tao C, Nogueira RG, Zhu Y, Sun J, Han H, Yuan G, Wen C, Zhou P, Chen W, Zeng G, et al. Trial of endovascular treatment of acute basilar‐artery occlusion. N Engl J Med. 2022;387:1361–1372. doi: 10.1056/NEJMoa2206317 [DOI] [PubMed] [Google Scholar]
  • 3. Gupta D, D'Anna L, Klein P, Araujo‐Contreras R, Kaliaev A, Abdalkader M, Hu W, Nguyen TN. Endovascular treatment for basilar artery occlusion. J Clin Med. 2024;13:4153. doi: 10.3390/jcm13144153 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Cai L, Wang L, Campbell BCV, Wu Y, Abdalkader M, Alemseged F, Kaesmacher J, Puetz V, Nagel S, Strbian D, et al. Endovascular thrombectomy with versus without intravenous thrombolysis in patients with acute basilar artery occlusion: a systematic review and meta‐analysis. J Neurol. 2024;271:3039–3049. doi: 10.1016/j.jstrokecerebrovasdis.2022.106847 [DOI] [PubMed] [Google Scholar]
  • 5. Tian S, Zou M, Li D, Zhou H, Wang C, Liu Q, Gao L. Efficacy and safety of thrombectomy with or without intravenous thrombolysis in the treatment of acute basilar artery occlusion ischemic stroke: an updated systematic review and meta‐analysis. Front Neurol. 2024;15:1433158. doi: 10.3389/fneur.2024.1433158 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Lapergue B, Blanc R, Costalat V, Desal H, Saleme S, Spelle L, Marnat G, Shotar E, Eugene F, Mazighi M, et al. Effect of thrombectomy with combined contact aspiration and stent retriever vs stent retriever alone on revascularization in patients with acute ischemic stroke and large vessel occlusion. JAMA. 2021;326:1158–1169. doi: 10.1001/jama.2021.13827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Wischmann J, Zimmermann H, Keidel L, Liebig T, Nolte CH, Kellert L. Aspiration only versus stent retriever only thrombectomy in basilar artery occlusion: a propensity score‐matched analysis of the German stroke Registry. J Neurointerv Surg. 2024;17:e393–e399. doi: 10.1136/jnis-2024-021797 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Fan Z, Li F, Chen H, Zhang L, Ji B. Aspiration versus stent retriever thrombectomy in posterior circulation stroke: a systematic review and meta‐analysis. Eur Neurol. 2022;85:424–436. doi: 10.1159/000525406 [DOI] [PubMed] [Google Scholar]
  • 9. Bernsen MLE, Bruggeman AAE, Brouwer J, Emmer BJ, Majoie CBLM, Coutinho JM, Goldhoorn R‐JB, van Oostenbrugge RJ, van Zwam WH, van der Leij C, et al. Aspiration versus stent retriever thrombectomy for posterior circulation stroke. Stroke. 2022;53:749–757. doi: 10.1161/STROKEAHA.121.034926 [DOI] [PubMed] [Google Scholar]
  • 10. Pop R, Räty S, Riva R, Marnat G, Dobrocky T, Alexandre PL, Lefebvre M, Albucher JF, Boulanger M, Di Maria F, et al. Effect of bridging thrombolysis on the efficacy of stent retriever thrombectomy techniques. Clin Neuroradiol. 2024;34:93–103. doi: 10.1007/s00062-023-01340-9 [DOI] [PubMed] [Google Scholar]
  • 11. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806–808. doi: 10.1136/bmj.39335.541782.AD [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Von Kummer R, Broderick JP, Campbell BCV, Demchuk A, Goyal M, Hill MD, Treurniet KM, Majoie CBLM, Marquering HA, Mazya MV, et al. The heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke. 2015;46:2981–2986. doi: 10.1161/STROKEAHA.115.010049 [DOI] [PubMed] [Google Scholar]
  • 13. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, et al. Randomised double‐blind placebo‐controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245–1251. doi: 10.1016/s0140-6736(98)08020-9 [DOI] [PubMed] [Google Scholar]
  • 14. Feil K, Berndt MT, Wunderlich S, Maegerlein C, Bernkopf K, Zimmermann H, Herzberg M, Tiedt S, Küpper C, Wischmann J, et al. Endovascular thrombectomy for basilar artery occlusion stroke: analysis of the German stroke Registry‐endovascular treatment. Eur J Neurol. 2023;30:1293–1302. doi: 10.1111/ene.15694 [DOI] [PubMed] [Google Scholar]
  • 15. Nappini S, Arba F, Pracucci G, Saia V, Caimano D, Limbucci N, Renieri L, Zini A, Inzitari D, Toni D, et al. Bridging versus direct endovascular therapy in basilar artery occlusion. J Neurol Neurosurg Psychiatry. 2021;92:956–962. doi: 10.1136/jnnp-2020-325328 [DOI] [PubMed] [Google Scholar]
  • 16. Nie X, Wang D, Pu Y, Wei Y, Lu Q, Yan H, Liu X, Zheng L, Liu J, Yang X, et al. Endovascular treatment with or without intravenous alteplase for acute ischaemic stroke due to basilar artery occlusion. Stroke Vasc Neurol. 2022;7:190–199. doi: 10.1136/svn-2021-001242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Uno J, Kameda K, Otsuji R, Ren N, Nagaoka S, Maeda K, Ikai Y, Gi H. Mechanical thrombectomy for acute basilar artery occlusion in early therapeutic time window. Cerebrovasc Dis. 2017;44:217–224. doi: 10.1159/000479939 [DOI] [PubMed] [Google Scholar]
  • 18. Langezaal LCM, van der Hoeven EJRJ, Mont'Alverne FJA, de Carvalho JJF, Lima FO, Dippel DWJ, van der Lugt A, Lo RTH, Boiten J, Lycklama à Nijeholt GJ, et al. Endovascular therapy for stroke due to basilar‐artery occlusion. N Engl J Med. 2021;384:1910–1920. doi: 10.1056/NEJMoa2030297 [DOI] [PubMed] [Google Scholar]
  • 19. Kaneko J, Ota T, Tagami T, Unemoto K, Shigeta K, Amano T, Ueda M, Matsumaru Y, Shiokawa Y, Hirano T. Endovascular treatment of acute basilar artery occlusion: Tama‐REgistry of acute thrombectomy (TREAT) study. J Neurol Sci. 2019;401:29–33. doi: 10.1016/j.jns.2019.04.010 [DOI] [PubMed] [Google Scholar]
  • 20. Guo M, Yue C, Yang J, Hu J, Guo C, Peng Z, Xu R, Yang D, Kong W, Liu X, et al. Thrombectomy alone versus intravenous thrombolysis before thrombectomy for acute basilar artery occlusion. J Neurointerv Surg. 2024;16:794–800. doi: 10.1136/jnis-2023-020361 [DOI] [PubMed] [Google Scholar]
  • 21. Knapen RRMM, Bernsen MLE, Langezaal LCM, Olthuis SGH, Michel P, Hofmeijer J, Vos J, van Kuijk SMJ, Majoie CB, Emmer BJ, et al. Aspiration versus stent retriever thrombectomy in basilar‐artery occlusion; results from the BASICS trial. Stroke Vasc Interv Neurol. 2023;3:e000768. doi: 10.1161/SVIN.122.000768 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Maïer B, Finitsis S, Mazighi M, Lapergue B, Marnat G, Sibon I, Richard S, Cognard C, Viguier A, Olivot J, et al. Thrombectomy with or without intravenous thrombolytics in basilar artery occlusion. Ann Neurol. 2023;94:596–604. doi: 10.1002/ana.26720 [DOI] [PubMed] [Google Scholar]
  • 23. Siow I, Tan BYQ, Lee KS, Ong N, Toh E, Gopinathan A, Yang C, Bhogal P, Lam E, Spooner O, et al. Bridging thrombolysis versus direct mechanical thrombectomy in stroke due to basilar artery occlusion. J Stroke. 2022;24:128–137. doi: 10.5853/jos.2021.02082 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Mujanovic A, Yogendrakumar V, Ng FC, Gattringer T, Serrallach BL, Meinel TR, Churilov L, Nistl O, Zheng S, Mitchell PJ, et al. Effect of Thrombolytics on delayed reperfusion after incomplete thrombectomy. Neurology. 2025;104:e213641. doi: 10.1212/WNL.0000000000213641 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Tang T, Li D, Zhao M, Thomas AM, Chuang C, Fan T, Li S. The effect of intravenous thrombolysis on patients with successful thrombectomy depends on final reperfusion grade: a retrospective study. CNS Neurosci Ther. 2023;29:2377–2383. doi: 10.1111/cns.14227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Elawady SS, Kasem RA, Matsukawa H, Cunningham C, Sowlat MM, Nawabi NL, Orscelik A, Venegas JM, Isidor J, Loulida H, et al. The effect of intravenous thrombolysis in stroke patients with unsuccessful thrombectomy. Interv Neuroradiol. 2024;95:877–885. doi: 10.1177/15910199241279009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Katsanos AH, Malhotra K, Goyal N, Arthur A, Schellinger PD, Köhrmann M, Krogias C, Turc G, Magoufis G, Leys D, et al. Intravenous thrombolysis prior to mechanical thrombectomy in large vessel occlusions. Ann Neurol. 2019;86:395–406. doi: 10.1002/ana.25544 [DOI] [PubMed] [Google Scholar]
  • 28. Alawieh A, Vargas J, Fargen KM, Langley EF, Starke RM, De Leacy R, Chatterjee R, Rai A, Dumont T, Kan P, et al. Impact of procedure time on outcomes of thrombectomy for stroke. J Am Coll Cardiol. 2019;73:879–890. doi: 10.1016/j.jacc.2018.11.052 [DOI] [PubMed] [Google Scholar]
  • 29. Zaidat OO, Castonguay AC, Linfante I, Gupta R, Martin CO, Holloway WE, Mueller‐Kronast N, English JD, Dabus G, Malisch TW, et al. First pass effect. Stroke. 2018;49:660–666. doi: 10.1161/STROKEAHA.117.020315 [DOI] [PubMed] [Google Scholar]
  • 30. D'Anna L, Falzon A, Wong OY, Erla J, Christos N, Spooner O, Banerjee S, Zhang L, Simister R. Comparison of mothership versus drip‐and‐ship models for endovascular treatment of basilar artery occlusion in the London metropolitan area. Stroke Vasc Interv Neurol. 2024;4:e001077. doi: 10.1161/SVIN.123.001077 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. D'Anna L, Foschi M, Dixon L, Bax F, Levee V, Fayez F, Knight L, Cella A, Mare’ A, Kuris F, et al. Predictors of futile recanalization after intravenous thrombolysis in stroke patients transferred for endovascular treatment. J Thromb Thrombolysis. 2025;58:232–242. doi: 10.1007/s11239-025-03070-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Prabhakaran S, Gonzalez NR, Zachrison KS, Adeoye O, Alexandrov AW, Ansari SA, Chapman S, Czap AL, Dumitrascu OM, Ishida K, et al. 2026 guideline for the early Management of Patients with Acute Ischemic Stroke: a guideline from the American Heart Association/American Stroke Association. Stroke. 2026;57:e316–e436. doi: 10.1161/STR.0000000000000513 [DOI] [PubMed] [Google Scholar]
  • 33. Wang L, Hao M, Wu N, Wu S, Fisher M, Xiong Y. Comprehensive review of Tenecteplase for thrombolysis in acute ischemic stroke. J Am Heart Assoc. 2024;13:e031692. doi: 10.1161/JAHA.123.031692. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

STROBE checklist

Tables S1‐S12

Figures S1‐S7


Articles from Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease are provided here courtesy of Wiley

RESOURCES